May 16, 2024

Multiplexed In Vivo Screening Using Barcoded Aptamer Technology to Identify Oligonucleotide-Based Targeting Reagents

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Recent FDA approvals of mRNA vaccines, short-interfering RNAs, and antisense oligonucleotides highlight the success of oligonucleotides as therapeutics. Aptamers are excellent affinity reagents that can selectively label protein biomarkers, but their clinical application has lagged. When formulating a given aptamer for

Me gusta

Guardar

Cite This Study

Thomas et al. (Thu,) studied this question.

synapsesocial.com/papers/68e69b09b6db64358762115b https://doi.org/https://doi.org/10.1089/nat.2024.0010

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment2019 · 2,224 citations
2Fiji: an open-source platform for biological-image analysis2012 · 70,911 citations
3The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis2016 · 791 citations
4FDA approves second RNA aptamer2023 · 65 citations
5Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer2008 · 182 citations

Me gusta

Guardar